Compare ProShares Ultra QQQ ETF (QLD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ProShares Ultra QQQ ETF trades at $98.43 (market cap $15.38B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: ProShares Ultra QQQ ETF is the larger of the two by market cap, and ProShares Ultra QQQ ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 36 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| QLD | XBI | |
|---|---|---|
Market Cap | $15.38B | $10.11B |
Volume | 4,844,085 | 12,903,266 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $100.77 | $169.55 |
52-Week Low | $57.16 | $104.99 |
Typical Hold Time | 36 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $97.56, down 2.66% amid broader market volatility. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $96 and resistance at $100. The ETF provides 2x leveraged exposure to the Nasdaq-100, attracting institutional interest as evidenced by recent buying activity from 180 Wealth Advisors. Recent news highlights QLD's resilience compared to higher-leverage alternatives during market downturns.
The outlook for QLD remains tied to Nasdaq-100 performance and Federal Reserve policy. While technical momentum appears positive, investors face amplified volatility risks inherent to leveraged products. The ETF's 2x leverage structure offers middle-ground exposure that may appeal to tactical investors seeking Nasdaq-100 upside with less extreme risk than 3x products.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
